Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.63 |
| ▸ | ACP1 | P24666 | 3/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8900656 | 0.99 | TOP2A (0.65) | TOP2AACP1APPMEN1KMT2A | |
| SCHEMBL8890898 | 0.90 | APP (0.58) | TOP2AACP1APPMEN1KMT2A | |
| SCHEMBL30125103 | 0.90 | APP (0.58) | TOP2AACP1APPMEN1KMT2A | |
| SCHEMBL4088578 | 0.88 | CYP1A2 (0.72) | TOP2AACP1MEN1KMT2AMAPT | |
| SCHEMBL1091141 | 0.85 | TOP2A (0.64) | TOP2AACP1APPMEN1KMT2A | |
| SCHEMBL1090545 | 0.84 | TOP2A (0.67) | TOP2AACP1APPMEN1KMT2A | |
| SCHEMBL1085090 | 0.83 | ACP1 (0.84) | TOP2AACP1MEN1KMT2AMAPT | |
| SCHEMBL1085411 | 0.82 | ACP1 (0.87) | TOP2AACP1MEN1KMT2AMAPT | |
| SCHEMBL30125072 | 0.79 | ACKR3 (0.49) | ACP1APPMEN1KMT2AMAPT | |
| SCHEMBL8900229 | 0.79 | ACKR3 (0.49) | ACP1APPMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| EP-1778670-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM Pharma A/S (DK) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010446-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | TOP2A 4884/4885ACP1 958/4885APP 4522/4885 |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | TOP2A 27/4885ACP1 2031/4885APP 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.